Διεγράφησαν τα μη εξοφληθέντα πρόστιμα μη εμβολιασθέντων κατά covid-19

Σε χθεσινό ΦΕΚ δημοσιεύθηκε η διαγραφή όσων προστίμων ΔΕΝ ΕΞΟΦΛΗΘΗΣΑΝ για τους ΜΗ ΕΜΒΟΛΙΑΣΜΕΝΟΥΣ κατά covid-19

COVID-19 Updates

January 19, 2024
Amount of Respiratory Illness Is Elevated or Increasing in Most Areas of the Country



Respiratory Virus Data Channel Weekly Snapshot
The amount of respiratory illness (fever plus cough or sore throat) causing people to seek healthcare is elevated or increasing across most areas of the country. CDC’s Respiratory Virus Data Channel provides a summary of the key viral respiratory illness findings for COVID-19, flu, and RSV. CDC continues to anticipate this fall and winter respiratory illness season will likely result in a similar number of hospitalizations as last season. Vaccination remains the best way to protect yourself against serious outcomes of COVID-19, flu, and RSV (if eligible for RSV vaccine).

Learn More



Where to Find FREE COVID-19 Testing
CDC’s Increasing Community Access to Testing (ICATT) program will continue to provide no-cost COVID-19 testing for uninsured people who are symptomatic or exposed. More than 19,000 ICATT sites will also offer no-cost COVID-19 vaccines to adults without health insurance and adults without full vaccine insurance coverage. This website helps you find ICATT COVID-19 testing locations and contact information for the providers. You can also visit your state, tribal, local, or territorial health department’s website to find the latest local information on testing.
Learn More



Benefits of Antiviral Treatment for COVID-19 Outweigh Potential Risks of Reboun
If you get sick with COVID-19 and are at higher risk for severe illness, antiviral treatments are available that can reduce your risk of hospitalization and death. But it’s important to get on treatment within 5-7 days after you first develop symptoms.
Rebound, a return of symptoms or a new positive test after having tested negative, has been reported in people with and without the use of COVID-19 antivirals. Current evidence suggests rebound presents as mild symptoms 3-7 days after initial illness resolves. If you are at high risk for severe COVID-19, treatment benefits outweigh the potential risks of rebound.

Learn More



Updated Guidance for Healthcare Providers on Increased Supply of RSV Immunization to Protect Babies

Nirsevimab is an RSV antibody immunization recommended for preventing severe RSV in infants and some young children. Supply of nirsevimab was limited earlier in the season, and CDC provided guidance to healthcare providers on how to prioritize the limited supply. But with recent increases in supply, CDC now advises healthcare providers to return to recommendations put forward by CDC and the Advisory Committee on Immunization Practices (ACIP) on the use of nirsevimab in babies and young children. Infants and children recommended to receive nirsevimab should be immunized as quickly as possible. RSV antibody immunization is recommended for all infants who are younger than 8 months, born during or entering their first RSV season, and some children between 8-19 months who are at increased risk for severe RSV and entering their second RSV season. Most infants whose mothers received an RSV vaccine do not need to also get an RSV antibody.

Learn More

Centers for Disease Control and Prevention

1600 Clifton Rd Atlanta, GA 30329 1-800-CDC-INFO (800-232-4636) TTY: 888-232-6348

EUROPEAN MEDICINES AGENCY:Midterm report on 2025 network strategy highlights good progress during critical period of the pandemic

Midterm report on 2025 network strategy highlights good progress during critical period of the pandemic

20 December 2023
The midterm report of the European Medicines Agencies Network Strategy (EMANS) finds the pandemic strengthened the network and supported transformative change in the European system across key strategic areas.
NewsCorporate

Page contents

Related document
Related content
Contact point


The European medicines regulatory network is on track to meet its strategic goals and objectives covering availability and accessibility of medicines; data analytics, digital tools, and digital transformation; innovation; antimicrobial resistance and other emerging health threats; supply-chain challenges; sustainability of the network and operational excellence, according to the midterm report of the network strategy.

“Despite the unprecedented challenges presented by the COVID-19 pandemic and the resource that has been deployed across the medicines regulatory network in response, a lot of progress has been made in the six priority focus areas of our network strategy,” says Emer Cooke, EMA’s Executive Director. “The end of the public health emergency and the lifting of the business continuity planning means we will once again be in a position to focus more fully on delivering patient-relevant medicines and digital transformation while continuing to deal with health threats and supply issues.”

The network strategy was published in December 2020 by EMA and the Heads of Medicines Agencies (HMA). As the main strategy guiding the delivery of the operational, regulatory, and scientific output of the EU medicines regulatory system, the EMANS identified shared challenges, goals, and priorities for a five-year period, to give strategic direction to the work of the European medicines regulatory network.

Karl Broich, Chair of the HMA Management Group, said: “The European medicines regulatory network, with its unique way of collaborating and pooling scientific and regulatory expertise across Europe, has just emerged from three long years of the COVID-19 health emergency. Difficult periods often serve to stress test systems and reveal facture lines and valuable learnings. From the network’s point of view, this experience has strengthened the desire to continue building together a better regulatory system and all the priorities envisioned as part of the EMANS.”

The midterm report offers a snapshot of achievements from January 2021 to June 2023. It revisits the original goals and objectives as well as the actions proposed to deliver them. According to the report, the original proposal remains valid and relevant. EMA and HMA will continue to deliver successfully on the remaining actions.
Background on EMANS

The EMANS sets out how the network continues to enable the supply of safe and effective medicines, adapting to new developments in science, medicine, digital technologies, globalisation and emerging health threats, such as antimicrobial resistance (AMR) and the COVID-19 pandemic. It was built following an extensive period of outreach, analysis, and consultation with EMA’s scientific committees, stakeholders, and EU regulatory partners through a public consultation before its final publication in December 2020.

The strategy outlined six priority focus areas in line with the European Commission's roadmap for a Pharmaceutical strategy for Europe. Initial work on the pandemic was fed into the strategy's development and the numerous lessons learned from COVID-19 will continue to inform future reviews of the strategy and subsequent work plans. The EMANS identifies strategic goals and objectives for each focus areas, which were subsequently translated by EMA and the HMA into concrete actions in their respective detailed work plans and programmes. Implementation of the EMANS also took place through the Regulatory Science Strategy (RSS) to 2025. Mid-point reporting of the RSS includes key achievements to March 2023 (which are also reflected here) and we have elaborated on further achievements since.

NotesRegulatory science refers to the range of scientific disciplines that are applied to the quality, safety and efficacy assessment of medicinal products and that inform regulatory decision-making throughout the lifecycle of a medicine. It encompasses basic and applied biomedical and social sciences and contributes to the development of regulatory standards and tools.

Related document
European medicines agencies network strategy to 2025: Mid-point report to Q2 2023
First published:20/12/2023
English (EN) (1.29 MB - PDF)View

CDC:Antivirals Can Protect Against Severe Illness from COVID-19

December 22, 2023
This message includes updates on COVID-19 from CDC.

Antivirals and COVID-19

Antivirals are an important tool for treating people with COVID-19 but are often underused. COVID-19 antivirals help reduce hospitalizations and deaths among people at higher risk, especially people 65 years and older and those with certain underlying conditions. COVID-19 antivirals need to be prescribed more often to people who are at risk for severe illness to reduce hospitalizations and save lives.


If You Get Sick with COVID-19, Antiviral Treatments Can Protect You Against Severe Illness

With COVID-19 hospitalizations on the rise, it is important that people who get sick and are at higher risk for severe illness get on treatment in the first days of illness, since symptoms can change and worsen quickly. While these antivirals are effective at preventing severe disease, not enough people are taking them.

Antivirals can provide additional protection, even if you are vaccinated, if:
You are at least 50 years of age, especially 65 and older, OR
You have certain underlying medical conditions, such as a weakened immune system, heart disease, obesity, diabetes, or chronic lung disease, regardless of your age

If you get sick with COVID-19, you should talk to a medical provider about getting treatment if you fall into either of these two categories. Find out more.

Centers for Disease Control and Prevention

1600 Clifton Rd Atlanta, GA 30329 1-800-CDC-INFO (800-232-4636) TTY: 888-232-6348

The Delivery - Remarkable stories from the COVID-19 vaccine delivery efforts

 

 

The-Delivery.org is now live

Over the past three years, the global health and science community has made public health history. For 1221 days, countries fought to save lives and prevent serious illness as we endeavored to make COVID-19 vaccines available everywhere.

 

The-Delivery.org is a digital vaccine carrier box, a time capsule of sorts, preserving the stories and scientific findings of the COVID-19 vaccine delivery efforts. 

Within it, you’ll find everything from the number of lives saved by the vaccine to the financial burden the rollout placed on countries, to the logistics behind the journey of a vaccine vial around the globe. 

 

 

 

Putting faces to the numbers, human stories from the frontline are interwoven throughout – stories that were uncovered by working with a network of photojournalists to document vaccine deliveries in the most challenging environments.

Now, it is time to process our incredible journey, reflecting on the lessons of COVID-19 vaccine delivery so we can better prepare for the future.

 

To help media organizations tell the story of COVID-19, we have made The Delivery available to all media under a Creative Commons license – meaning the text, imagery and other assets are freely available to be used by our media partners. Should you have any questions about what this means or how to get hold of the work in formats which work for you and your organization, please don't hesitate to get in touch.

 

 

  Forward 

www.the-delivery.org

COVID-19 Testing, Self-Tests (At-Home Tests)

November 1, 2023
COVID-19 Testing, Self-Tests (At-Home Tests)



Get 4 Free COVID-19 Tests

Every U.S. household can order 4 more free COVID-19 self-tests.
Self-tests (also called at-home tests and over-the-counter tests) are one of several tools that protect you and others by reducing the chances of spreading COVID-19.

Self-tests can be taken at home or anywhere, are easy to use, and produce rapid results.

You can place an order
Online at COVIDTests.gov
By calling 1-800-232-0233 (TTY 1-888-720-7489)
By calling or emailing the Disability Information and Access Line (DIAL) at 1-888-677-1199 or DIAL@usaginganddisability.org (for people with disabilities)

Learn More



Things to Consider When Taking A COVID-19 Test

When you get tested for COVID-19:

Make sure to test at the right time
Choose the right type of test for your circumstance
Follow test directions as recommended by FDA

Visit CDC’s website to learn more about COVID-19 testing, including how and when to use a self-test, and other things to keep in mind when you take a COVID-19 test.

Many of us may have expired COVID-19 self-tests. Before you throw out “expired” COVID-19 self-tests, check to see if their expiration dates have been extended.
The expiration date is the date through which the test is expected to perform as accurately as when manufactured. Sometimes, a test’s expiration date is extended.
You can check FDA’s website to find more information on the test, including if the expiration date has been extended, how the test performs, and other details that may help you decide what test is right for you.
To learn more about COVID-19 testing, visit:
COVID-19 Testing: What You Need to Know| CDC
To see if the expiration date for your at-home COVID-19 tests has been extended, visit: At-Home OTC COVID-19 Diagnostic Tests | FDA



Take Precautions If You Have COVID-19
If you have COVID-19, you can take precautions to protect yourself and others.

Stay home and separate yourself from others
Improve ventilation (air flow) at home
Wear a high-quality mask when you’re around others
Ask a healthcare provider about treatments that may be available to you

Learn More



Stay Informed with the COVID Data Tracker
COVID Data Tracker provides the most recent data and trends on COVID-19 test positivity, emergency department visits, hospitalizations, and deaths. You can explore data on hospital admission levels to learn how COVID-19 is impacting your area, and also find information on variants and wastewater surveillance.
Learn More



How to Get Your COVID-19, Flu, and RSV Vaccines This Year
Immunizations are available this fall and winter in the United States that can help protect against three major respiratory diseases: COVID-19, flu, and RSV. Immunization against these viruses remains the best protection for reducing the risk of serious illness, hospitalizations, long-term health impacts, and death.
Recommendations for these immunizations vary based on age, pregnancy status, or medical conditions. To learn more, including how to find recommended immunizations, visit: How to Get Your Flu, COVID-19, and RSV Vaccines This Year | CDC

Updates to This Newsletter

CDC is expanding the information you receive through this COVID-19 newsletter to also include information on protecting yourself and loved ones against other respiratory viruses. 

Centers for Disease Control and Prevention

1600 Clifton Rd Atlanta, GA 30329 1-800-CDC-INFO (800-232-4636) TTY: 888-232-6348

Εμβολιασμός κατά Covid-19 2023-2024 με το Μονοδύναμο Επικαιροποιημένο Εμβόλιο

 

Ενημέρωση για τον Εμβολιασμό του πληθυσμού κατά της Covid-19 για την περίοδο 2023-2024 με το Μονοδύναμο Επικαιροποιημένο Εμβόλιο (XBB.1.5)

16/10/2023

Αθήνα 16 Οκτωβρίου 2023

ΔΕΛΤΙΟ ΤΥΠΟΥ

Ενημέρωση για τον Εμβολιασμό του πληθυσμού κατά της Covid-19 για την περίοδο 2023-2024 με το Μονοδύναμο Επικαιροποιημένο Εμβόλιο (XBB.1.5).

Η Πρόεδρος της Εθνικής Επιτροπής Εμβολιασμών, Μαρία Θεοδωρίδου και η Αναπληρώτρια Υπουργός Υγείας, Ειρήνη Αγαπηδάκη ενημέρωσαν  τους συντάκτες υγείας σχετικά με τον εμβολιασμό του πληθυσμού για την περίοδο 2023-2024 με το Επικαιροποιημένο Εμβόλιο κατά της Covid-19.

Κατά την διάρκεια της συνέντευξης τύπου, παρουσιάστηκαν οι αναλυτικές οδηγίες για τον εμβολιασμό του πληθυσμού κατά της Covid-19 με το επικαιροποιημένο εμβόλιο.

Βασικά σημεία της ενημέρωσης

Σχετικά με το νέο Επικαιροποιημένο Εμβόλιο κατά της Covid-19

Η Εθνική Επιτροπή Εμβολιασμών συστήνει για την χρονική περίοδο 2023/24, τον εμβολιασμό έναντι της COVID-19 με το επικαιροποιημένο εμβόλιο, των ατόμων εκείνων που βρίσκονται σε αυξημένο κίνδυνο για σοβαρή νόσο λόγω ηλικίας, υποκείμενου νοσήματος ή κατάστασης και συγκεκριμένα:

• Άτομα ηλικίας 60 ετών και άνω
• Άτομα ηλικίας 6 μηνών έως 59 ετών με υποκείμενα νοσήματα και καταστάσεις που αυξάνουν τον κίνδυνο σοβαρής νόσου
• Άτομα με ανοσοκαταστολή
• Έγκυες γυναίκες
• Επαγγελματίες υγείας

The COVID-19 Vaccine Delivery Partnership | Final Update (June 2023)

 

June 2023 | Issue 07

 

Thank you and farewell

Dear partners,

Over the past year and a half, much has been achieved to reduce global inequities in COVID-19 vaccination coverage. With sufficient vaccine supply, countries have had the opportunity to vaccinate. The AMC92 today have a coverage of 55%, compared to 28% in January 2022.  Coverage in the 34 countries for concerted support has increased nearly tenfold from 3% to 29%.   Although gaps persist and the work continues, we have seen progress in countries dealing with humanitarian emergencies and a substantial increase in coverage among high-priority groups as countries deployed more tailored vaccination approaches. 

While the PHEIC has been declared over, the work on COVID-19 vaccination is not.  With the COVID-19 Vaccine Delivery Partnership transitioning at the end of June, support from Gavi, UNICEF, WHO, and partners continues as countries pursue integration with a focus on reaching high-priority groups and the recovery of essential immunization.  

As I move into my new position as UNICEF Deputy Executive Director for Humanitarian Action and Supply Operations,  I wanted to thank you for the excellent collaboration and partnership we have received.   It has been rewarding and meaningful to work with you.  

Best regards.

Ted Chaiban

 

 

Unseen

COVID-19 vaccine delivery efforts reminded us of the crucial role health and community workers play. But we are losing health workers due to unfair pay, poor conditions and overwork. By 2030, the world will have a shortage of 10 million health workers. Now’s our time to support the people who keep us alive and safe.

The COVID-19 Vaccine Delivery Partnership

 

April 2023 | Issue 06

 

Mali: Vaccinating on the Borderlands

With a population of just over 20 000, Ménaka is the largest outpost in the Malian southeast frontier with Niger.

Regional security is volatile and violence is present: armed groups attack and constrict routes between Ménaka and its nearest neighbouring localities, Anderamboukane and Ansongo. 

As a result, people are displaced and on the move from the Ader Douchi hills to what is the nearest town with services, Ménaka. They need safety and shelter—but they also need vaccines. In December 2022 Ménaka and its surroundings were included in a Malian vaccination campaign against COVID-19. The vaccines are to be sent in by plane for delivery 1500 kilometres away. 

The journey starts in the capital, Bamako. Read the photo story.

 

 

 

COVID-19 Vaccine Delivery Partnership Situation Report

This report covers the months of February and March 2023.

In this edition:

• Overview: Global Situation | High-priority groups | 92 Advance Market Commitment Countries | 34 countries for concerted support
• In-depth: Community health workers and vaccine delivery
• Country snapshot: Pakistan and Liberia

 

 

COVID-19 Vaccine Delivery Stories

Boosting vaccinations among African populations suffering humanitarian crises

The health systems in 16 African countries get more resilient to epidemics of vaccine-preventable diseases, and their national immunization programmes stronger with support from the European Union. WHO implements a project for boosting COVID-19 vaccinations in vulnerable communities. The partnership is bringing results across Africa, as at-risk populations receive life-saving vaccines thanks to the hard work of community mobilizers, health staff and WHO teams. Read more

DRC: Ted Chaiban explique à la presse Congolaise le cadre de sa visite à Kinshasa

Mali: "Until they're all vaccinated, I'm not giving myself peace." 

Mozambique: Teenagers in Mozambique Participate in Countrywide COVID-19 Vaccination Campaign

India: COVID-19 vaccination is rising in many vulnerable African communities

Zimbabwe: Zimbabwe National COVID-19 Response Documentary Trailer

Africa: Compendium of human Interest stories This compendium provides a glimpse of how the sustained efforts of the GAVI-UNICEF partnership have touched the lives of many – across states, communities, and cultures

Sierra Leone: Protecting Girls in Sierra Leone from COVID-19 and Cervical Cancer Through Joint Vaccination Events

Mozambique: Teenagers in Mozambique Participate in Countrywide COVID-19 Vaccination Campaign

Sierra Leone: Protecting Girls in Sierra Leone from COVID-19 and Cervical Cancer Through Joint Vaccination Events

Global partners announce a new effort – “The Big Catch-up” – to vaccinate millions of children and restore immunization progress lost during the pandemic 

The State of the World’s Children 2023  

#BuildBackImmunity A global campaign to reach children who have missed out on vaccines

More stories

 

Resources, Reports and Technical Guidance

NEW: SAGE updates COVID-19 vaccination guidance

Following its 20-23 March meeting, WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) revised the roadmap for prioritizing the use of COVID-19 vaccines, to reflect the impact of Omicron and high population-level immunity due to infection and vaccination. 

WHO SAGE Roadmap for prioritizing uses of COVID-19 vaccines

Good practice statement on the use of variant-containing COVID-19 vaccines

Considerations to inform country COVID-19 vaccine decision-making

COVID-19 Vaccine Delivery Partnership Information Hub

COVID-19 Vaccine Implementation Analysis & Insights Report archives

Management and safe disposal of COVID-19 vaccination waste at health facility level

WHO/UNICEF guidance document on programmatic considerations for C-19 integration into PHC

Improving Immunization Coverage and Equity Technical Resources Contains resources on improving coverage and equity of immunization services. Intended users of the collection include managers of national immunization programs and EPI & PHC technical advisers and partners. There are three browsing options: by topic, by question or by the IRMMA Framework for Zero-Dose.

Immunization Decision-Making Resource Catalogue Contains resources to support vaccine decision-making. Intended users include country-level decision-makers at all levels in the health sector, international partner organizations, and other policy making and coordination bodies. The catalogue is organized by different criteria used in decision-making. Moreover, overview of decision-support tools is included that can help structure a transparent and evidence-based decision-making process.

 

All COVID-19 vaccine delivery resources

COVID-19 vaccines

Global Compendium of country knowledge on COVID-19 vaccination

Tools and guidance on vaccine confidence and uptake

All WHO COVID-19 vaccine resources: toolkit

All WHO COVID-19 technical guidance AR EN ES FR RU ZH 

 

 

Coming up

Global Stocktake of COVID-19 Vaccine Delivery

A global stocktake is being convened to reflect on achievements of COVID-19 delivery in concerted support countries, identify lessons learned and good practices, develop critical actionable recommendations for integration into primary health care and where possible support recovery of essential immunization.

The meeting is scheduled to take place on 2-3 May 2023 in Addis Ababa, Ethiopia. It will be co-hosted by the Ethiopia Federal Ministry of Health and jointly convened with CoVDP, WHO, UNICEF, Gavi and other Stakeholders. Read more

 

Learning Collective Initiative in Covid-19 Vaccine Delivery Partnership

This initiative series aims to collect and share key learnings, best practices and challenges in planning and implementing COVID-19 vaccination uptake. Slides and recordings from past sessions as well as registration links for future sessions are available here. For more information on the topic of integration, see: Country experiences to date on integrating C-19 vaccination

 

Call for Abstracts

The 17th TechNet Conference will take place in Panama City, Panama in the Region of the Americas (PAHO). The conference will begin on Monday, October 16, 2023 and finish on Thursday, October 19, 2023. More information. 

Submit your ideas for a presentation or poster that will be featured at the conference here.  

 

The Vaccination Acceptance Research Network 2023 Conference

The Sabin Vaccine Institute and UNICEF, In Partnership With Gavi, The Vaccine Alliance present the Vaccination Acceptance Research Network (Varn) 2023 Conference

 

The COVID-19 Vaccine Delivery Partnership Transition

The next phase of COVID-19 vaccine delivery sees us transitioning to a new approach. This will ensure our efforts will create long-lasting benefits that will be seen beyond the COVID-19 pandemic. Vaccine equity - for all vaccines - is one of the great responsibilities of our lifetime. The work towards closing this gap continues.

Read more about the transition of the COVID-19 Vaccine Delivery Partnership:
Questions and Answers
About the COVID-19 Vaccine Delivery Partnership Transition